Compare Google Inc (GOOG) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Google Inc vs Merck & Co., Inc. — how do they compare? Google Inc trades at $371.56 (market cap $4.52T), while Merck & Co., Inc. trades at $127.73 (market cap $305.29B). The key difference: Google Inc is far larger — about 14.8× Merck & Co., Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.75%). Which is the better fit depends on your goals.
| GOOG | MRK | |
|---|---|---|
Market Cap | $4.52T | $305.29B |
Volume | 1,511,127 | — |
Sector | Technology | Health |
52-Week High | $399.06 | $129.52 |
52-Week Low | $183.77 | $77.60 |
Enterprise Value | $4.49T | $348.71B |
Dividend Yield | 0.24% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GOOG trades at $357.33, up 1.9% today, with a bullish technical signal and strong support at $353. The company shows robust fundamentals with 2025 revenue of $402.84B, net income of $132.17B, and a net margin of 32.8%. Recent earnings beats and a consensus analyst price target of $457.50 highlight positive momentum, while news includes Warren Buffett's endorsement and strategic AI partnerships.
Outlook remains positive driven by earnings growth and AI expansion, but risks include regulatory fines and competitive pressures. Wall Street sentiment is strongly bullish with 87% buy ratings, suggesting upside potential, though investors should monitor execution and macroeconomic factors.
Merck (MRK) trades at $120.80, down 2.6% on the day, with technical indicators showing a bullish moving average signal but neutral oscillators. The company reported strong recent earnings beats and maintains solid profitability with a 73.91% gross margin and 13.59% net margin. Recent news highlights Merck's acquisition of Terns Pharmaceuticals for approximately $6.7 billion to bolster its oncology pipeline, while institutional investors continue accumulating shares.
The outlook remains positive with analyst consensus at Buy (67.57%) and a $137.30 price target, suggesting 13.7% upside. Key risks include integration challenges from the Terns acquisition, competitive pressures in oncology, and potential regulatory headwinds. Strong cash flow generation ($16.47B operating cash flow in 2025) supports continued dividend payments and strategic investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
